Some content of this application is unavailable at the moment.
If this situation persist, please contact us atFeedback&Contact
1. (WO2019025432) ANTICANCER PEPTIDES
Latest bibliographic data on file with the International Bureau    Submit observation

Pub. No.: WO/2019/025432 International Application No.: PCT/EP2018/070714
Publication Date: 07.02.2019 International Filing Date: 31.07.2018
IPC:
C07K 7/08 (2006.01) ,C07K 14/00 (2006.01) ,A61K 47/54 (2017.01) ,A61K 38/00 (2006.01) ,C07K 19/00 (2006.01)
C CHEMISTRY; METALLURGY
07
ORGANIC CHEMISTRY
K
PEPTIDES
7
Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
04
Linear peptides containing only normal peptide links
08
having 12 to 20 amino acids
C CHEMISTRY; METALLURGY
07
ORGANIC CHEMISTRY
K
PEPTIDES
14
Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
[IPC code unknown for A61K 47/54]
A HUMAN NECESSITIES
61
MEDICAL OR VETERINARY SCIENCE; HYGIENE
K
PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
38
Medicinal preparations containing peptides
C CHEMISTRY; METALLURGY
07
ORGANIC CHEMISTRY
K
PEPTIDES
19
Hybrid peptides
Applicants:
IDP DISCOVERY PHARMA, S.L. [ES/ES]; Baldiri Reixac Nº 4 08028 BARCELONA, ES
Inventors:
NEVOLA, Laura; ES
ESTEBAN MARTÍN, Santiago; ES
Agent:
ZBM PATENTS - ZEA, BARLOCCI & MARKVARDSEN; Pl. Catalunya, 1 2nd floor 08002 BARCELONA, ES
Priority Data:
17382530.801.08.2017EP
Title (EN) ANTICANCER PEPTIDES
(FR) PEPTIDES À ACTIVITÉ ANTICANCÉREUSE
Abstract:
(EN) The present invention provides a peptide of formula (I) or a pharmaceutical salt thereof wherein "m", "n", "p", and "q" represent integers and are selected from 0 and 1; and "r" is comprised from 1 to 10; a linker birradical of formula (II), which is connecting an alpha carbon atom of an amino acid located at position "i" in the peptide sequence of formula (I) with an alpha carbon atom of an amino acid located at position "i+4" or "i+7"in the peptide sequence of formula (I); a C-terminal end corresponding to –C(O)R4; and a N-terminal end corresponding to –NHR5. Alternatively, the present invention provides a peptide or a pharmaceutical salt thereof which has an amino acid sequence with an identity from 85% to 95% with respect to sequence SEQ ID NO: 9: The peptides of the invention show anticancer activity. (I)
(FR) La présente invention concerne un peptide de formule (I) ou un sel pharmaceutique de celui-ci, dans la formule "m", "n", "p" et "q" représentent des nombres entiers et sont choisis parmi 0 et 1 ; et "r" est compris entre 1 et 10 ; un lieur biradical de formule (II), qui est relié à un atome de carbone alpha d'un acide aminé situé à la position "i" dans la séquence peptidique de formule (I) avec un atome de carbone alpha d'un acide aminé situé à la position "i+4" ou "i+7" dans la séquence peptidique de formule (I) ; une extrémité C-terminale correspondant à –C(O)R4 ; et une extrémité N-terminale correspondant à –NHR5. Selon une variante, la présente invention concerne un peptide ou un sel pharmaceutique de celui-ci qui a une séquence d'acides aminés ayant une identité de 85 % à 95 % par rapport à la séquence SEQ ID NO : 9 : les peptides de l'invention présentent une activité anticancéreuse. (I)
front page image
Designated States: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW
African Regional Intellectual Property Organization (ARIPO) (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW)
Eurasian Patent Office (AM, AZ, BY, KG, KZ, RU, TJ, TM)
European Patent Office (EPO) (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR)
African Intellectual Property Organization (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG)
Publication Language: English (EN)
Filing Language: English (EN)